What's hot

View all perspectives
What's Hot
Sleep asleep

Sleep Quality & Psoriatic Arthritis

For people living with psoriatic arthritis (PsA), the comfort of a good night's sleep may feel out of reach for many.

Read more →

Ultrasound in PsA

Dr. Arthur Kavanaugh discusses abstract 2206 presented at ACR22 in Philadelphia. Abstract 2206: Understanding Inter-rater Variability in Scoring of Entheseal Lesions: Results from the Diagnostic Ultrasound Enthesitis Tool (DUET) Study

Watch video →

Tapering TNFi in nonradiographic AxSpA

Dr. Peter Nash at ACR22 Convergence in Philadelphia, PA.

Watch video →

Sunday (Day 2): ACR 22 Daily Recap

ACR 2022 Daily Recap for Sunday, November 13th. Panelists: Drs. Robert Chao, Antoni Chan, Bella Mehta, Janet Pope, Yuz Yusof, Cassy Sims, Akhil Sood, Sheila Reyes and Jack Cush.

Watch video →

Spondyloarthritis: Novel Therapies, Diagnostic Dilemmas and Depression

Dr. Lianne Gensler discusses the following abstracts presented at ACR22 Convergence. Abstracts 1597, 1598, 1599 (treatment) and 1613, 1609 and 1614 (diagnosis and outcomes)

Watch video →

Deucravacitinib in PsA

Dr. Arthur Kavanaugh discusses abstract 1598 at ACR22 Convergence in Philadelphia. Abstract 1598: Safety and Efficacy of Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Patients with Psoriatic Arthritis: 52-Week Results from a Randomized Phase 2 Trial

Watch video →

Sarilumab in Polymyalgia Rheumatica: Results from SAPHYR Trial

Dr. Michael Putman interviews Dr. Robert Speira about abstract 1676 presented at the ACR22 Convergence meeting in Philadelphia, PA. Abstract 1676: Sarilumab in Patients with Relapsing Polymyalgia Rheumatica: A Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Trial (SAPHYR)

Watch video →

Best of ACR Day Two in PSA

Watch video →

PET CT Imaging to Define Risk of Progression from PSO to PsA

Dr. Peter Nash discusses Abstract 1018 at ACR22 Convergence.

Watch video →

ACR22 Daily Recap: Saturday Recap

Panelists: Drs. Jack Cush, Michael Putman, Eric Dein, Patricia Harkins and Rachel Tate. 

Watch video →
      RT @doctorRBC: Don't forget the power of NSAIDs! (esp COX2i)
      10 year study from Germany.
      NSAID intake associated with lo

      Robert B Chao, MD doctorRBC

      3 years 1 month ago
      Don't forget the power of NSAIDs! (esp COX2i) 10 year study from Germany. NSAID intake associated with lower radiographic progression in axSpA patients (esp r-axSpA) COX2i may have stronger effect #ACRBest #ACR22 @RheumNow Abs#1492 https://t.co/vPIaCahmiW
      RT @uptoTate: Prevalence of uveitis in patients with PsA was about 5%. Uveitis rate decreased w/ anti-TNFα monoclonal a

      Dr. Rachel Tate uptoTate

      3 years 1 month ago
      Prevalence of uveitis in patients with PsA was about 5%. Uveitis rate decreased w/ anti-TNFα monoclonal antibodies and increased w/ ETN and SECU. Abs 1159 #ACR22 @RheumNow https://t.co/BtHMQ6apNI https://t.co/uZEYVQdiOU
      RT @RichardPAConway: Corriere et al Duloxetine and gabapentin have similar rates of MI and stroke in non-cancer pain. Th

      Richard Conway RichardPAConway

      3 years 1 month ago
      Corriere et al Duloxetine and gabapentin have similar rates of MI and stroke in non-cancer pain. There was some theoretical concern that duloxetine could increase risk but not evident here @RheumNow #ACR22 Abstr#1195 https://t.co/E3S9Md5XWq https://t.co/8KMtcU6d1B
      RT @RichardPAConway: Sattui @SattuiSEMD Treatment patterns in US in 26,102 PMR patients from RISE. Over 24 months <3%

      Richard Conway RichardPAConway

      3 years 1 month ago
      Sattui @SattuiSEMD Treatment patterns in US in 26,102 PMR patients from RISE. Over 24 months <3% used IL6i, 36% DMARD. DM and morbid obese more likely to use. Women, older, and using IL6i/DMARD more likely to have GC>1 year @RheumNow #ACR22 Abstr#1546 https://t.co/Imjsgyo49j https://t.co/8E5Rj5d7Pz
      RT @JulianSegan: Data from CorEvitas RA registry shows persistence for first-line monotherapy with etanercept, adalimuma

      Julian Segan JulianSegan

      3 years 1 month ago
      Data from CorEvitas RA registry shows persistence for first-line monotherapy with etanercept, adalimumab and JAKis no different at 12 months. 20-25% switching at 12-months. Clearly more to secondary failure than anti-drug antibodies. @RheumNow #ACR22 https://t.co/FeP0UAykUg https://t.co/ad9w9lI0Hu
      RT @RHEUMarampa: Nice study on referral strategies for #axSpA in pts w/ chronic LBP by Dr @Nellziade
      🔸MASTER strateg

      sheila RHEUMarampa

      3 years 1 month ago
      Nice study on referral strategies for #axSpA in pts w/ chronic LBP by Dr @Nellziade 🔸MASTER strategy-optimal reference strategy: IBP, ✅NSAID response, HLA-B27+ & +SpA family hx 🔸Clinical predictive factors: uveitis, IBP, Pso, enthesitis &🚹 #ACR22 @RheumNow ABST#1512 #ACRBest https://t.co/l6AleXX7Kt
      RT @uptoTate: Decreased colonic mucus production in HLA-B27 + healthy individuals and axSpA and IBD pts. Abs 1151 #ACR22

      Dr. Rachel Tate uptoTate

      3 years 1 month ago
      Decreased colonic mucus production in HLA-B27 + healthy individuals and axSpA and IBD pts. Abs 1151 #ACR22 @RheumNow https://t.co/CwX4n6PJFy https://t.co/4f1Za0Qhpj
      RT @doctorRBC: Biologics to treat gut microbiome dysbiosis??
      In axSpA pts treated with bDMARDs for one year, gut microbi

      Robert B Chao, MD doctorRBC

      3 years 1 month ago
      Biologics to treat gut microbiome dysbiosis?? In axSpA pts treated with bDMARDs for one year, gut microbiome resembled those of controls. Collinsella remained stable - possible biomarker? Abs#1162 @RheumNow #ACR22 #ACRBest https://t.co/vmQFJMpNPP
      RT @uptoTate: Abs 1153 at #ACR22 males may have a higher levels of Th17-associated transcription factors. Radiographic p

      Dr. Rachel Tate uptoTate

      3 years 1 month ago
      Abs 1153 at #ACR22 males may have a higher levels of Th17-associated transcription factors. Radiographic progression in men may be mediated by S100 proteins and prostaglandins. @RheumNow https://t.co/mWbsaB8kK8 https://t.co/IkTBZcaqa6
      RT @RichardPAConway: Arora @BichileT et al. PJP prophylaxis practice among nephrologists and rheumatologists @RheumNow #

      Richard Conway RichardPAConway

      3 years 1 month ago
      Arora @BichileT et al. PJP prophylaxis practice among nephrologists and rheumatologists @RheumNow #ACR22 Abstr#1282 https://t.co/3VyJR6k76U https://t.co/VM5rnbmv9h
      We want to see how you are taking in #ACR22! Share your favorite pictures from ACR on Twitter and tag #RheumPix and #ACR

      Dr. John Cush RheumNow

      3 years 1 month ago
      We want to see how you are taking in #ACR22! Share your favorite pictures from ACR on Twitter and tag #RheumPix and #ACR22 and we'll re-tweet our favorite ones! https://t.co/iUY4azQQyD
      pill pillbox adherence
      Medication adherence is a problem
      3 years 1 month ago
      Much has been written about tapering medications in rheumatic diseases, often due to high costs of medications, a desire to avoid side effects and patient preference to take less medications (especially if they have side effects). This is countered by something we all know: medications not taken don’t work, and those that are frequently missed may not provide optimal outcomes for the majority of patients.
      RT @RichardPAConway: Raadsen et al. RA-specific CV risk specifically targets pre-existing atherosclerotic vessels. So if

      Richard Conway RichardPAConway

      3 years 1 month ago
      Raadsen et al. RA-specific CV risk specifically targets pre-existing atherosclerotic vessels. So if no baseline CVD, traditional risk factors are main driver rather than RA. Risk without prevalent CVD (HR 1.16 95%CI 0.88 –1.53) @RheumNow #ACR22 Abstr#1408 https://t.co/1Y6WeEFmim https://t.co/qG3RMNnbqt
      RT @RichardPAConway: Michailidou et al. PMR has increased neutrophil activation and NET formation. Elevated calprotectin

      Richard Conway RichardPAConway

      3 years 1 month ago
      Michailidou et al. PMR has increased neutrophil activation and NET formation. Elevated calprotectin. Immune complexes assoc neutrophil activation. Neutrophil activation inhibited by FcγRIIA blockade @RheumNow #ACR22 Abstr#1545 https://t.co/EAqZ3byMoP https://t.co/T2PmIExSKj
      RT @RichardPAConway: Sarsam @sclerodermaUM et al. Long term follow up of abatacept in SSc (ASSET). @RheumNow #ACR22 Abst

      Richard Conway RichardPAConway

      3 years 1 month ago
      Sarsam @sclerodermaUM et al. Long term follow up of abatacept in SSc (ASSET). @RheumNow #ACR22 Abstr#1521 https://t.co/BvWSSSIqN0 https://t.co/kc2HxjkVh8

      Podcasts

      • ACR2022 - Day 4 00:14:40
      • Monday ACR 2022 Daily Recap 00:37:20
      • ACR2022 - Day 3.3 00:34:23

      Catch up on Conference Podcasts

      ×